Featured Studies

Multiple sclerosis (MS) is a disease that damages the central nervous system (brain and spinal cord). This leads to increased physical disability over time. The disease is lifelong once it begins. Researchers want to learn more about the stages of multiple sclerosis and follow them until a person's death to understand how the physical and clinical signs of MS relate to its changes over time.

The National Institutes of Health (NIH) is looking for volunteers who use opiates regularly or who are receiving treatment for opiate use. The purpose is to learn how opiates affect brain function.

National Cancer Institute (NCI) researchers are conducting a study of patients with rare central nervous system (CNS) tumors. More than 130 primary rare CNS (brain or spine) tumors have been identified. Most affect less than 2,000 people in the United States each year. This study will test whether stimulating the immune system using the drug nivolumab can shrink select rare brain or spine tumors or increase the time it takes for them to grow or spread.

Researchers at the National Institutes of Health (NIH) Clinical Center seek healthy volunteers for a research study on opioid use disorder (OUD). The purpose of this research study is to learn how opiate use disorder affects dopamine signaling in the brain of people dependent on opioids.

Fanconi anemia is a rare genetic disorder that mostly affects children and often leads to bone marrow failure. Researchers at the National Institutes of Health (NIH) are investigating a new drug to improve blood counts in individuals diagnosed with Fanconi anemia. Eltrombopag is an oral drug that mimics a special protein that causes the body to make more platelets. Currently eltrombopag is used to treat low platelet counts in patients with hepatitis C and chronic immune thrombocytopenic purpura (ITP). Researchers are evaluating if this new drug will improve blood cell counts in individuals diagnosed with Fanconi anemia.

Severe aplastic anemia is a rare and serious blood disorder. Patients with severe aplastic anemia commonly receive Cyclosporine to help improve blood counts. When cyclosporine treatment stops, the disease may return in one in three people. Researchers at the National Institutes of Health (NIH) Clinical Center are studying if sirolimus, an immunosuppressant, can help prevent a relapse in patients diagnosed with severe aplastic anemia following cyclosporine treatment.

Researchers at the NIH Clinical Center are seeking healthy children for a study of growth and health behaviors. The purpose of the study is to better understand growth in children and adolescents.